Terrie Curran has bought stock on 2 days since May 2022

Terrie Curran is a biopharmaceutical executive and board member who has served on the board of directors of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) since November 2020.( At Arcutis, she contributes to corporate governance as a member of the Nominating and Corporate Governance Committee, bringing extensive leadership experience across immunology, gastroenterology, dermatology, and women’s health to the company’s medical dermatology portfolio.(

Curran retired in April 2025 as CEO and President of Phathom Pharmaceuticals, a late‑clinical‑stage biopharmaceutical company focused on treatments for gastrointestinal diseases.( Previously, she was President, Global Inflammation and Immunology (I&I) Franchise and a member of the executive committee at Celgene, where she led U.S. commercial operations for I&I and oversaw the successful launch of Otezla® for moderate to severe plaque psoriasis.( Earlier in her career, she served as Senior Vice President and General Manager, Global Women’s Health at Merck & Co., and held general management and commercial roles at Schering‑Plough and Pharmacia.( Curran has also served on the boards of Myovant Sciences and H. Lundbeck A/S, and holds both a Bachelor of Applied Science and a Graduate Diploma in Marketing from the University of Technology Sydney.(

Written by Perplexity from public sources.